Please wait while we load the requested 10-Q report or click the link below:
For Investors: Rebecca Peterson, (781) 609-6378
For Media: Jennifer Snyder, (781) 609-6166
Overall Financial Expectations for Fiscal 2011
|§||Revenues of $44.0 million, driven by strong manufacturing and royalty revenues from RISPERDAL® CONSTA®. Worldwide sales of RISPERDAL CONSTA by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen-Cilag (Janssen) were approximately $388 million. For the calendar year ended December 31, 2010, worldwide sales of RISPERDAL CONSTA were $1.5 billion.|
|§||GAAP net loss of $11.4 million and pro forma net loss of $5.6 million.|
|§||Positive cash flow from operations of $12.9 million.|
|§||Strong financial position, with cash and total investments of $285.0 million as of December 31, 2010.|
|§||Alkermes collaborative partner, Amylin Pharmaceuticals, Inc. (Amylin), announced that the U.S. Food and Drug Administration (FDA) provided written approval of the study design for a thorough QT (tQT) study for BYDUREON. With the approval of the study design, Amylin intends to commence the study in February 2011 and plans to submit the results of this study to the FDA in the second half of calendar 2011.|
|§||Expanded ALKS 33 clinical program into treatment-resistant depression (TRD). Phase 1/2 study to commence in the second half of calendar 2011.|
Page 1 of 7
The following information was filed by Alkermes Inc on Thursday, February 3, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Alkermes Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alkermes Inc.